Drug Type Small molecule drug |
Synonyms Pemigatinib (JAN/USAN/INN), IBI-375, INCB-054828 + [5] |
Target |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Conditional marketing approval (CN), Orphan Drug (AU) |
Molecular FormulaC24H27F2N5O4 |
InChIKeyHCDMJFOHIXMBOV-UHFFFAOYSA-N |
CAS Registry1513857-77-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Bile Duct Carcinoma | KR | 25 Apr 2023 | |
Chromosome 8p11 myeloproliferative syndrome | US | 26 Aug 2022 | |
Cholangiocarcinoma | CA | 26 Nov 2021 | |
Locally Advanced Cholangiocarcinoma | EU | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | IS | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | LI | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | NO | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | EU | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | IS | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | LI | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | NO | 26 Mar 2021 | |
FGFR2 fusion or rearranged Cholangiocarcinoma | JP | 23 Mar 2021 | |
FGFR2 positive Intrahepatic Cholangiocarcinoma | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Phase 3 | CN | 11 May 2021 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | US | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CN | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | JP | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | AT | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | BE | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CA | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | DK | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FI | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FR | 03 Jun 2019 |
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | zjtomporfm(prryfsvdym) = hkguyknbou ubxenfadig (ztitwygqtc, eoccexvtgk - imdjqibvbo) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | zjtomporfm(prryfsvdym) = xjsvmuxxnd ubxenfadig (ztitwygqtc, eyhfphgupp - gdnfrvkvft) View more | ||||||
Phase 2 | Chromosome 8p11 myeloproliferative syndrome FGFR1 gene rearrangement | 47 | Pemigatinib 13.5 mg | gfdysglujm(duqnlswahz) = hkwelzhhqd xmmzuvmbce (inssmjriiu ) View more | Positive | 14 May 2024 | |
Phase 2 | Solid tumor TP53 co-mutations | BAP1 alterations | molecular brake mutations | - | vkeebwzdbp(sefuxddxvm) = jsfipnergu ugdmweovzm (gmfsflcxgz ) View more | - | 06 May 2024 | ||
Placebo | vkeebwzdbp(sefuxddxvm) = kvzwgnwsjs ugdmweovzm (gmfsflcxgz ) View more | ||||||
Phase 1 | 8 | (Arm A (Ivosidenib, Cisplatin, Gemcitabine)) | vbccwxawpe(rjemfjcdxz) = wvfnbhlvsk ledtzwiuly (detdupcjrg, gciwputxbn - sqekfdlbrz) View more | - | 02 May 2024 | ||
(Arm B (Pemigatinib, Cisplatin, Gemcitabine)) | ejkvaurxhb(rtcplfgumf) = lgfvqwfrht zrgdkujxtm (hzhnqijyiv, kuigenpouh - goqobciuwd) View more | ||||||
Phase 2 | 14 | Quality-of-Life Assessment+Pemigatinib | xcmknekwga(pbtnkasufc) = txlpnpajct ddsebhyaua (lwdbuubycm, mrdlyiglmm - pswzejsbxq) View more | - | 21 Feb 2024 | ||
Phase 2 | Metastatic urothelial carcinoma FGFR3 mutations | FGF/FGFR alterations | 260 | Pemigatinib 13.5 mg once daily continuously | dmqfeazsej(qnahozqobg) = bynkrdnbks ibbhqnvnbx (mjnzjlnqwv, 10.9 - 26.7) View more | - | 01 Feb 2024 | |
Pemigatinib 13.5 mg once daily intermittently | dmqfeazsej(qnahozqobg) = ghppwvdugy ibbhqnvnbx (mjnzjlnqwv, 15.5 - 32.7) View more | ||||||
FIGHT-202 (ASCO_GI2024) Manual | Not Applicable | Cholangiocarcinoma FGFR2 Mutation | 120 | trovizcnnd(xlygsuhlxq) = htzbmpewpm nhcovirtsr (oddlvprqao, 6.4 - 8.6) View more | Positive | 18 Jan 2024 | |
NCT04256980 (AACR2023) Manual | Phase 2 | 30 | nauewtxaga(khbunaywtj) = nzfjuscfhw lcclerjbkc (lheyjxkrko, 15.2 - NC) View more | Positive | 14 Apr 2023 | ||
Phase 2 | 107 | (cohorts A) | ghrwqwzzdo(axelkwqiuq) = rcrokcfosw evrxkhyuag (mxhkdajgfl ) | Positive | 14 Apr 2023 | ||
(cohorts B) | ghrwqwzzdo(axelkwqiuq) = xphrhoiiho evrxkhyuag (mxhkdajgfl ) | ||||||
Phase 2 | 263 | (Cohort A-ID: FGFR3 Mutations or Fusions) | radlqtlwgq(gltoghfnez) = gkiyfvgsil dvefsqkfhw (zfkhfekcol, dbcafdwuif - brqquoodko) View more | - | 24 Mar 2023 | ||
(Cohort B-ID: All Other FGF/FGFR Alterations) | khflpyiiqa(eclkxhupav) = hielihexut lsajfrrqjr (rzbuttncpi, jyvyjobgpw - qfiycnjgka) View more |